Dapagliflozin Patent Expiration
Dapagliflozin is used for treating heart failure and type 2 diabetes. It was first introduced by Astrazeneca Ab
Dapagliflozin Patents
Given below is the list of patents protecting Dapagliflozin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Farxiga |
US12213988 (Pediatric) | Methods Of Treating Chronic Kidney Disease With Dapagliflozin | Oct 01, 2041 | Astrazeneca Ab |
| Farxiga |
US12409186 (Pediatric) | Methods Of Treating Chronic Kidney Disease With Dapagliflozin | Oct 01, 2041 | Astrazeneca Ab |
| Farxiga | US12213988 | Methods of treating chronic kidney disease with dapagliflozin | Apr 01, 2041 | Astrazeneca Ab |
| Farxiga | US12409186 | Methods Of Treating Chronic Kidney Disease With Dapagliflozin | Apr 01, 2041 | Astrazeneca Ab |
| Farxiga |
US10973836 (Pediatric) | Methods of treating heart failure with reduced ejection fraction | Sep 09, 2040 | Astrazeneca Ab |
| Farxiga |
US11903955 (Pediatric) | Methods of treating heart failure with reduced ejection fraction | Sep 09, 2040 | Astrazeneca Ab |
| Farxiga | US10973836 | Methods of treating heart failure with reduced ejection fraction | Mar 09, 2040 | Astrazeneca Ab |
| Farxiga | US11903955 | Methods of treating heart failure with reduced ejection fraction | Mar 09, 2040 | Astrazeneca Ab |
| Farxiga |
US11826376 (Pediatric) | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | Jan 18, 2040 | Astrazeneca Ab |
| Farxiga |
US12472194 (Pediatric) | Methods Of Treating Heart Failure With Preserved Ejection Fraction Employing Dapagliflozin And Compositions Comprising The Same | Jan 18, 2040 | Astrazeneca Ab |
| Farxiga | US11826376 | Methods of treating heart failure with preserved ejection fraction employing dapagliflozin and compositions comprising the same | Jul 18, 2039 | Astrazeneca Ab |
| Farxiga | US12472194 | Methods Of Treating Heart Failure With Preserved Ejection Fraction Employing Dapagliflozin And Compositions Comprising The Same | Jul 18, 2039 | Astrazeneca Ab |
| Farxiga |
US8685934 (Pediatric) | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof | Nov 26, 2030 | Astrazeneca Ab |
| Farxiga |
US8721615 (Pediatric) | Ampoule comprising an ampoule holder | Jul 18, 2030 | Astrazeneca Ab |
| Farxiga |
US7919598 (Pediatric) | Crystal structures of SGLT2 inhibitors and processes for preparing same | Jun 16, 2030 | Astrazeneca Ab |
| Farxiga | US8685934 | Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof | May 26, 2030 | Astrazeneca Ab |
| Farxiga | US8721615 | Ampoule comprising an ampoule holder | Jan 18, 2030 | Astrazeneca Ab |
| Farxiga | US7919598 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 16, 2029 | Astrazeneca Ab |
| Farxiga |
US7851502 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Feb 19, 2029 | Astrazeneca Ab |
| Farxiga |
US8221786 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Sep 21, 2028 | Astrazeneca Ab |
| Farxiga |
US8361972 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Sep 21, 2028 | Astrazeneca Ab |
| Farxiga |
US8716251 (Pediatric) | Pharmaceutical formulations containing an SGLT2 inhibitor | Sep 21, 2028 | Astrazeneca Ab |
| Farxiga | US7851502 | Pharmaceutical formulations containing an SGLT2 inhibitor | Aug 19, 2028 | Astrazeneca Ab |
| Farxiga | US8221786 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Farxiga | US8361972 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Farxiga | US8716251 | Pharmaceutical formulations containing an SGLT2 inhibitor | Mar 21, 2028 | Astrazeneca Ab |
| Farxiga |
US8501698 (Pediatric) | Crystal structures of SGLT2 inhibitors and processes for preparing same | Dec 20, 2027 | Astrazeneca Ab |
| Farxiga | US8501698 | Crystal structures of SGLT2 inhibitors and processes for preparing same | Jun 20, 2027 | Astrazeneca Ab |
| Farxiga |
US8329648 (Pediatric) | Methods for treating diabetes and reducing body weight | Feb 18, 2027 | Astrazeneca Ab |
| Farxiga |
US8906851 (Pediatric) | Method for treating diabetes | Feb 18, 2027 | Astrazeneca Ab |
| Farxiga | US8329648 | Methods for treating diabetes and reducing body weight |
Aug 18, 2026
(Expired) | Astrazeneca Ab |
| Farxiga | US8906851 | Method for treating diabetes |
Aug 18, 2026
(Expired) | Astrazeneca Ab |
| Farxiga |
US6515117 (Pediatric) | C-aryl glucoside SGLT2 inhibitors and method |
Apr 04, 2026
(Expired) | Astrazeneca Ab |
| Farxiga |
US7456254 (Pediatric) | Polymer-based sustained release device |
Dec 30, 2025
(Expired) | Astrazeneca Ab |
| Farxiga |
US8431685 (Pediatric) | Polymer-based sustained release device |
Oct 13, 2025
(Expired) | Astrazeneca Ab |
| Farxiga |
US8461105 (Pediatric) | Polymer-based sustained release device |
Oct 13, 2025
(Expired) | Astrazeneca Ab |
| Farxiga | US6515117 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2025
(Expired) | Astrazeneca Ab |
| Farxiga | US7456254 | Polymer-based sustained release device |
Jun 30, 2025
(Expired) | Astrazeneca Ab |
| Farxiga | US8431685 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Farxiga | US8461105 | Polymer-based sustained release device |
Apr 13, 2025
(Expired) | Astrazeneca Ab |
| Farxiga | US9238076 | Polymer-based sustained release device |
Apr 15, 2024
(Expired) | Astrazeneca Ab |
| Farxiga | US6414126 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Farxiga | US6936590 | C-aryl glucoside SGLT2 inhibitors and method |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
| Farxiga | US9198925 | Pharmaceutical formulations containing an SGLT2 inhibitor |
Oct 04, 2020
(Expired) | Astrazeneca Ab |
Dapagliflozin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Dapagliflozin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
